A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

This study has been completed.

Sponsors and Collaborators:	Astellas Pharma Inc Astellas Pharma US, Inc.
Information provided by:	Astellas Pharma Inc
ClinicalTrials.gov Identifier:	NCT00257478

Purpose

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Condition	Intervention	Phase
Prostate Cancer Cancer of Prostate Prostatic Cancer Cancer of the Prostate	Drug: YM155	Phase II

MedlinePlus related topics: Cancer Prostate Cancer

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257478

Locations

United States, Arizona

Tuscon, Arizona, United States, 85724
United States, California

Los Angeles, California, United States, 90033
United States, Idaho

Coeur d'Alene, Idaho, United States, 83814
United States, New York

New York, New York, United States, 10016

Bronx, New York, United States, 10461
United States, Pennsylvania

Philadelphia, Pennsylvania, United States, 19111
United States, Texas

San Antonio, Texas, United States, 78229
Netherlands

Amsterdam, Netherlands
United Kingdom, Surry

Sutton, Surry, United Kingdom, SM2 5Pt

Sponsors and Collaborators

Astellas Pharma Inc

Astellas Pharma US, Inc.

Investigators

Study Director:

D. Buell, MD

Astellas Pharma US, Inc.

More Information

Study ID Numbers:	155-CL-007
Study First Received:	November 22, 2005
Last Updated:	May 9, 2007
ClinicalTrials.gov Identifier:	NCT00257478
Health Authority:	United States: Food and Drug Administration

Keywords provided by Astellas Pharma Inc:

Treatment Efficacy
Treatment Effectiveness
Disease Management
Treatment
Safety

Study placed in the following topic categories:

Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 13, 2009